FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine and represents a complex of nucleic acid and strongly branched cyclic dextrin representing glucan of a degree of polymerisation 50-5000, containing an internal branched cyclic structural fragment formed by alpha-1,4-glucoside bonds and at least one alpha-1,6-glucoside bonds and an external branched structural fragment bound to the internal branched cyclic structural fragment. The group of inventions also involves a composition containing of the diacylphosphatidylcholine, at least one compound specified in cholesterol, and a primary aliphatic amine, as well as the use and the method for cell delivery.
EFFECT: group of inventions provides low toxicity and high degree of safety; it is able to maintain the stable content of nucleic acid in a cell.
14 cl, 6 ex, 3 dwg
Title | Year | Author | Number |
---|---|---|---|
CARRIER COMPOSITION FOR WELL-TIMED DELIVERY OF NUCLEIC ACIDS | 2008 |
|
RU2476229C2 |
CARRIER COMPOSITION FOR NUCLEIC ACID TRANSPORT | 2006 |
|
RU2421227C2 |
TRANSPULMONARY LIPOSOME FOR CONTROLLING DRUG DELIVERY | 2008 |
|
RU2493874C2 |
COMPOSITION FOR INTRODUCING NUCLEIC ACID INTO CELLS | 2015 |
|
RU2715227C2 |
NUCLEIC ACID DELIVERY SYSTEM | 2002 |
|
RU2294192C2 |
PEPTIDES FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | 2020 |
|
RU2771605C2 |
COMPOSITION, IN STABLE CONDITION, SINGLE-STRANDED NUCLEIC ACID MOLECULE WHICH SUPPRESSES EXPRESSION OF GENE TGF-Β1 | 2016 |
|
RU2714257C2 |
HYBRID CARRIERS FOR DELIVERY OF NUCLEIC ACIDS | 2017 |
|
RU2751001C2 |
CHIRAL NUCLEIC ACID ADJUVANT | 2013 |
|
RU2677639C2 |
COMPLEXES OF NUCLEIC ACIDS | 2011 |
|
RU2568829C2 |
Authors
Dates
2012-10-27—Published
2008-11-06—Filed